{"created":"2023-05-15T16:43:01.871448+00:00","id":18216,"links":{},"metadata":{"_buckets":{"deposit":"33b38db9-dfa9-4ea3-9f48-1e3e97ff2ea8"},"_deposit":{"created_by":2,"id":"18216","owners":[2],"pid":{"revision_id":0,"type":"depid","value":"18216"},"status":"published"},"_oai":{"id":"oai:nagasaki-u.repo.nii.ac.jp:00018216","sets":["29:30"]},"author_link":["72613","72621","72620","72611","72614","72617","72618","72612","72619","72610","72616","72615"],"item_2_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2008-09-08","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"38","bibliographicPageEnd":"4968","bibliographicPageStart":"4962","bibliographicVolumeNumber":"26","bibliographic_titles":[{"bibliographic_title":"Vaccine"}]}]},"item_2_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"The levels of IgG determined by ELISA may have limited relevance in human\nimmunodeficiency virus (HIV)-infected adults because of nonfunctional antibodies. 58\nHIV-1-infected and 29 HIV-uninfected Ugandan adults were immunized with conjugate\nvaccine (CV) followed by polysaccharide vaccine (PV) after a two-month interval, and\nthe opsonophagocytic killing (OPK) titers against serotype 4 or 14 pneumococcal\nstrains as well as the levels of serotype-specific IgG in sera were determined.\nSignificant increases were found in the OPK titers and IgG levels for both serotypes\nafter CV vaccination irrespective of HIV status. Increases in IgG levels and OPK titers\nwere largely dependent on the CD4+ cell counts, except for increases in the IgG levels\nfor serotype 4. The proportions with serum OPK titer equal to or greater than 8 were\n0-4.3% for serotype 4 and 26.7-42.9% for serotype 14 before vaccination, but the\nproportions increased up to 43.3-86.2% for serotype 4 and 63.3-96.6% for serotype\n14 in all three groups 2 months after CV vaccination. The serum OPK titers remained at\nlevels higher than the pre-vaccination level for at least 8 months after CV vaccination. A\nsingle dose of CV could afford some protective immunity in HIV-infected African\nadults before the introduction of antiretroviral therapy.","subitem_description_type":"Abstract"}]},"item_2_description_63":{"attribute_name":"引用","attribute_value_mlt":[{"subitem_description":"Vaccine, 26(38), pp.4962-4968; 2008","subitem_description_type":"Other"}]},"item_2_publisher_33":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Elsevier BV"}]},"item_2_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1016/j.vaccine.2008.06.093","subitem_relation_type_select":"DOI"}}]},"item_2_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"c 2008 Elsevier Ltd All rights reserved"}]},"item_2_source_id_10":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AA10491877","subitem_source_identifier_type":"NCID"}]},"item_2_version_type_16":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Chen, Meng"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ssali, Francis"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Mulungi, Maureen"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Awio, Peter"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Yoshimine, Hiroyuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kuroki, Reiki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Furumoto, Akitsugu"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Tanimura, Susumu"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Kityo, Cissy"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nagatake, Tsuyoshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Mugyenyi, Peter"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Oishi, Kazunori"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-12-23"}],"displaytype":"detail","filename":"Vaccine26_4962.pdf","filesize":[{"value":"349.1 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"Vaccine26_4962.pdf","url":"https://nagasaki-u.repo.nii.ac.jp/record/18216/files/Vaccine26_4962.pdf"},"version_id":"4ec420b6-55e0-4209-a3ad-027252b5f66e"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Pneumococcal conjugate vaccine","subitem_subject_scheme":"Other"},{"subitem_subject":"pneumococcal polysaccharide vaccine","subitem_subject_scheme":"Other"},{"subitem_subject":"serotype-specific IgG","subitem_subject_scheme":"Other"},{"subitem_subject":"opsonophagocytic killing","subitem_subject_scheme":"Other"},{"subitem_subject":"HIV-infected adults","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Induction of opsonophagocytic killing activity with pneumococcal conjugate vaccine in human immunodeficiency virus-infected Ugandan adults","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Induction of opsonophagocytic killing activity with pneumococcal conjugate vaccine in human immunodeficiency virus-infected Ugandan adults"}]},"item_type_id":"2","owner":"2","path":["30"],"pubdate":{"attribute_name":"公開日","attribute_value":"2008-09-01"},"publish_date":"2008-09-01","publish_status":"0","recid":"18216","relation_version_is_last":true,"title":["Induction of opsonophagocytic killing activity with pneumococcal conjugate vaccine in human immunodeficiency virus-infected Ugandan adults"],"weko_creator_id":"2","weko_shared_id":-1},"updated":"2023-05-16T04:04:57.366214+00:00"}